Complete dataset included in the full report. Detailed tables, regional splits, forecasts, and methodologies are available with purchase.

Pitocin is a prescription injectable medication containing oxytocin, used to induce or strengthen labor by stimulating uterine contractions. It is administered intravenously and manufactured by Endo USA, Inc. This information was generated using AI and is provided for informational and research purposes only.

🔗 Related Datasets

• Oxytocin — HealthData.Gov
• Oxycodone hydrochloride — HealthData.Gov
• Oxycodone hydrochloride — HealthData.Gov
• Oxycodone hydrochloride — HealthData.Gov
• Oxycodone hydrochloride — HealthData.Gov

Where to buy Oxytocin: 64 vendors compared, $1.90/mg to $22.50/mg (median $6.00/mg), with COA status and transparency scores.

Corpus-verified analysis of 299 PubMed studies on Oxytocin. Includes evidence scores, target interactions, pathway associations, and research domain classification.

The table contains 27 products whose active ingredient are classified under the same pharmacologic class Oxytocin [CS].

The oxytocin market was valued at $1.52 billion in 2025 and is projected to reach $2.54 billion by 2034, growing at 5.8% CAGR.

This is an unblinded, sequential study of subjects; all participants will receive an infusion of oxytocin and intranasal administration of oxytocin with blood samples taken thereafter in order to create a formula to describe the concentrations of oxytocin in the blood over time (pharmacokinetics). In this study healthy volunteers. Participants will come to the Clinical Research Unit (CRU) on study day 1 and have two IVs inserted; one in each arm. Participants will get a 30 minute infusion through one of the IV catheters of oxytocin and blood will be taken several times over the next 120 minutes, plasma separated, and the amount of oxytocin measured in the plasma samples. Participants will come to the CRU on study day 2 and have one IV inserted; in the arm. Participants will self administer intranasal oxytocin and blood will be taken several times over the next 60 minutes and the amount of oxytocin measured in the plasma samples. This information will be analyzed by another group at Stanford University under a data sharing agreement between the institutions and funded by a grant from the National Institutes of Health. Compartmental modeling will be performed using NONMEM to describe the change in oxytocin concentrations over time. The effect of subject age, sex, race, ethnicity and weight on the pharmacokinetics of oxytocin will be examined, since these factors can affect pharmacokinetics and are important to better adjust the dose of drug to the individual. The main purpose of this study is to determine the amount of oxytocin in plasma after IV and i.n. administration. The research participants will not benefit from this study, but the knowledge investigators get will be important to adjust oxytocin dose to individuals, and to be able to calculate plasma oxytocin concentrations after various doses in the future. The sample size chosen is needed to get an accurate estimate for the parameters in the pharmacokinetic model for the population, not just the subjects in this study.

Oxytocin prices at 43 active online research vendors (66 comparable listings): lowest $2.28/mg, median $7.23/mg, every size and pack, plus the median across all comparable listings on each day a feed run read three or more vendors. Prices as scraped, converted to USD. Research use only.

Oxytocin vendors ranked by the lab reports they publish: coverage, verification, laboratory, results, freshness and public reviews.

48 third-party assay reports on Oxytocin across 6 batches and 6 suppliers, median purity 99.81 % area.

Experimental studies exploring the effects of intranasal oxytocin are typically underpowered due to small samples. Open access to experimental data and procedures and the use of previously employed measures is critical to building more robust and replicable findings, especially in less studied areas of oxytocin research. In this paper, data is provided from a double-blind placebo-controlled crossover study exploring the effects of intranasal oxytocin (IN-OT: 24 IU) on social preference to romantic partners, parents, peers, and strangers. Young adults (N=44; 91% female) in committed dating relationships completed three phases of data collection including a screening survey followed by two laboratory visits. In addition to romantic partner-, and stranger attraction ratings, the data is the first to provide comparisons between attachment and social preference ratings to parents, close friends, and romantic partners under placebo and IN-OT conditions. The data also include differences by situational and life history factors known to moderate oxytocin effects. The detailed protocol, and dataflow can be accessed to verify the analysis and findings or to conduct a replication study. The standardized experimental design and common IN-OT protocol add to the capacity for a meta-analysis exploring oxytocin effects on partner preference, and may also be directly ported to existing or future studies with related questions to increase sample size and power.

Oxytocin Injection Market was valued at USD 175 Million in 2025, projected to reach USD 270 Million by 2035 at a CAGR of 4.4%.

The dataset contains the files (DARE_Workfile, Empathy_Workfile) used for the analyses of the study published by Fragkaki and Cima (2019) in Psychoneuroendocrinology. The study examined the effect of oxytocin administration on empathy and emotion recognition in 100 male adolescents living in residential youth care facilities. The study had a randomized, double-blind, placebo-controlled, within-subject design. The study included 3 sessions: screening session and two experimental sessions. In the experimental sessions, the participants received oxytocin in one session and placebo in the other session and performed the same experimental tasks on empathy and emotion recognition 30 min after administration. The order of the sprays as well as the order of the tasks were randomized using computer randomization. We performed mixed modeling to examined the effect of oxytocin on the outcome variables. The file “Documentation-ReadMe” describes the trial information, methodology, and the variables included in the datasets. The file "icu_dutch" is the Dutch version of the Inventory of callous-unemotional traits, the file ctq_dutch" is the Dutch version of the Childhood trauma questionnaire", and the file "ades_dutch" is the Dutch version of the Adolescent dissociative experiences scale.

The magnocellular neurons (MCNs) in the hypothalamus selectively express either oxytocin (OXT) or vasopressin (AVP) neuropeptide genes, a property that defines their phenotypes. Here we examine the molecular basis of this selectivity in the OXT MCNs by stereotaxic microinjections of adeno-associated virus (AAV) vectors that contain various OXT gene promoter deletion constructs using EGFP as the reporter into the rat supraoptic nucleus (SON). Two weeks following injection of the AAVs, immunohistochemical assays of EGFP expression from these constructs were done to determine whether the EGFP reporter co-localizes with either the OXT- or AVP-immunoreactivity in the MCNs. The results show that the key elements in the OT gene promoter that regulate the cell-type specific expression the SON are located −216 to −100 bp upstream of the transcription start site. We hypothesize that within this 116 bp domain a repressor exists that inhibits expression specifically in AVP MCNs, thereby leading to the cell-type specific expression of the OXT gene only in the OXT MCNs.

Structured dataset of patents, exclusivities, generic approvals, litigation, and market intelligence for oxytocin.

Aggregated anonymized self-reports from PeptIQ users tracking Oxytocin.

Abstract: Affectionate touch, which is vital for mental and physical health, was restricted during the Covid-19 pandemic. This study investigated the association between momentary affectionate touch and subjective well-being, as well as salivary oxytocin and cortisol in everyday life during the pandemic. In the first step, we measured anxiety and depression symptoms, loneliness, and attitude toward social touch in a large cross-sectional online survey (N=1,050). From this sample, N=247 participants completed ecologically momentary assessments (EMA) over two days with six daily assessments by answering smartphone-based questions on affectionate touch and momentary mental state and providing concomitant saliva samples for cortisol and oxytocin assessment. Multilevel models showed that on a within-person level, affectionate touch was associated with decreased self-reported anxiety, general burden, stress, and increased oxytocin levels. On a between-person level, affectionate touch was associated with decreased cortisol levels and higher happiness. Moreover, individuals with a positive attitude towards social touch experiencing loneliness reported more mental health problems. Our results suggest that affectionate touch is linked to higher endogenous oxytocin in times of pandemic and lockdown and might buffer stress on a subjective and hormonal level. These findings might have implications for preventing mental burden during social contact restrictions.

17 published laboratory reports for Oxytocin.

Oxytocin Closed-Loop Infusion Controller Market Outlook

As per our latest research, the global oxytocin closed-loop infusion controller market size reached USD 466 million in 2025, reflecting robust adoption across healthcare settings worldwide. The market is projected to grow at a CAGR of 9.1% from 2026 to 2034, reaching an estimated USD 1,022 million by 2034. This strong growth trajectory is primarily driven by the rising prevalence of labor complications, increasing focus on maternal safety, and the rapid integration of advanced automation technologies in obstetric care. Historical data from 2019 through 2024 confirms a consistent upward trend, with adoption accelerating as healthcare systems in both developed and developing economies modernize their labor and delivery infrastructure.

One of the primary growth factors for the oxytocin closed-loop infusion controller market is the escalating need for precise and personalized drug administration during childbirth. Oxytocin is a critical hormone used for labor induction and the management of postpartum hemorrhage, but its administration requires careful titration to avoid adverse outcomes such as uterine hyperstimulation and fetal distress. Closed-loop infusion controllers, which automatically adjust oxytocin dosage based on real-time feedback from physiological parameters, significantly reduce the risk of under- or over-dosing. The growing awareness among healthcare professionals about the importance of controlled oxytocin delivery, combined with the rising incidence of high-risk pregnancies, is fueling the adoption of these advanced infusion controllers globally. Moreover, the increasing number of births in both developed and developing regions is amplifying the demand for safe and efficient labor management solutions.

Technological advancement in infusion systems represents another significant driver propelling market growth. The integration of sensor-based technologies, artificial intelligence (AI), and machine learning algorithms has revolutionized the capabilities of oxytocin closed-loop infusion controllers. These innovations enable real-time monitoring and adaptive dosing, enhancing patient safety and clinical outcomes. Similar innovation patterns are visible in adjacent fields such as vasopressor infusion control, where closed-loop automation is redefining hemodynamic management. The trend toward digitalization in healthcare, coupled with the proliferation of smart hospitals and maternity clinics, is fostering the deployment of integrated and connected infusion systems. The adoption of AI-driven controllers is particularly notable, as they offer predictive analytics and decision support, further optimizing oxytocin administration and reducing the burden on clinical staff.

The global market is also witnessing favorable regulatory developments and policy initiatives that support the adoption of advanced maternal health technologies. Governments and healthcare organizations are increasingly prioritizing maternal and neonatal safety, leading to investments in modernizing labor and delivery units. Funding for research and development in obstetric care devices, along with the establishment of stringent safety standards, is facilitating the commercialization and acceptance of oxytocin closed-loop infusion controllers. Furthermore, collaborations between medical device manufacturers, research institutions, and healthcare providers are accelerating innovation and expanding the market reach of these controllers, especially in regions with high maternal mortality rates.

From a regional perspective, North America currently holds the largest share of the oxytocin closed-loop infusion controller market, driven by advanced healthcare infrastructure, high awareness levels, and supportive reimbursement policies. Europe follows closely, with significant adoption in countries such as Germany, the United Kingdom, and France. The Asia Pacific region is poised for the fastest growth, fueled by increasing healthcare investments, rising birth rates, and government initiatives to improve maternal he

A collection of 12 brain maps. Each brain map is a 3D array of values representing properties of the brain at different locations.

Collection description